title: Clinicopathologic and prognostic differences between patients with hepatitis B- and C-related resectable hepatocellular carcinoma.
abstract: OBJECTIVE
  Hepatitis B and C viral infections are important factors in the development of hepatocellular carcinoma (HCC). This study examined the clinicopathologic and prognostic differences in patients with hepatitis B- and C-related resectable HCC.
  
  
  METHODS
  A total of 270 HCC patients who underwent hepatic resection were enrolled. Among these patients, 211 were positive for hepatitis B surface antigen (HBsAg) and 59 were positive for anti-hepatitis C virus antibody (anti-HCV). The clinical manifestations, pathologic features, and treatment outcomes were compared between the HBsAg-positive and anti-HCV-positive groups.
  
  
  RESULTS
  Compared to anti-HCV-positive patients, HBsAg-positive patients were significantly younger, had a higher familial incidence of HCC, larger tumor size, and a higher incidence of multiple tumors. HCC patients who were anti-HCV positive had worse liver function and a higher incidence of history of blood transfusion. DNA flow cytometric analysis revealed significantly more proliferative activity in the non-tumor part of the liver in HBsAg-positive HCC patients. The 1-, 3-, and 5-year overall survival rates of HBsAg-positive patients were 79%, 57%, and 48%, respectively, and for anti-HCV-positive patients were 91%, 75%, and 62%, respectively. HBsAg-positive patients had a significantly lower overall survival rate than anti-HCV-positive patients (p = 0.018).
  
  
  CONCLUSIONS
  HBsAg-positive patients with resectable HCC had a less favorable survival rate after tumor resection than anti-HCV-positive HCC patients. This survival difference might have been related to the relatively advanced stage of disease and the higher proliferative activity of the non-tumor part of the liver in HBsAg-positive HCC patients.
authors.affiliation: Department of Surgery, Veterans General Hospital, College of Medicine, National Yang-Ming University, Department of Biology and Anatomy, National Defense Medical Center, Taipei, Taiwan.
authors.forename: T H
authors.initials: TH
authors.lastname: Chen
authors.forename: L M
authors.initials: LM
authors.lastname: Tseng
authors.forename: G Y
authors.initials: GY
authors.lastname: Chau
authors.forename: W Y
authors.initials: WY
authors.lastname: Lui
authors.forename: S H
authors.initials: SH
authors.lastname: Tsay
authors.forename: K L
authors.initials: KL
authors.lastname: King
authors.forename: C C
authors.initials: CC
authors.lastname: Loong
authors.forename: C Y
authors.initials: CY
authors.lastname: Hsia
authors.forename: C W
authors.initials: CW
authors.lastname: Wu
mesh_terms: D000328:Adult; D000368:Aged; D006528:Carcinoma, Hepatocellular / Q000401:mortality / Q000473:pathology / Q000821:virology*; D005260:Female; D006498:Hepatectomy; D006514:Hepatitis B Surface Antigens / Q000097:blood*; D018937:Hepatitis C Antibodies / Q000097:blood*; D006801:Humans; D008113:Liver Neoplasms / Q000401:mortality / Q000473:pathology / Q000821:virology*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D015996:Survival Rate
chemical_list: D006514:Hepatitis B Surface Antigens; D018937:Hepatitis C Antibodies